X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product, which is being evaluated for the treatment of High-Risk JN.1 Variant Covid19 Infection.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome. It is being evaluated for the treatment of long covid.
Lead Product(s): TVGN 489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN 489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
The combined company will focus on the development of CD8+ cytotoxic T lymphocytes, including TVGN-489, for the treatment of infectious diseases, cancers, and neurological disorders.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Semper Paratus Acquisition Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 31, 2024
Details:
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the SARS-CoV-2 genome.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the entire SARS-CoV-2 genome.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.
Lead Product(s): T Cell Therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
TVGN-489 is highly purified cytotoxic CD8+ T lymphocytes designed to detect and kill SARS-CoV-2 infected cells. These allogeneic genetically unmodified CTLs are enriched and expanded in the lab and recognize proteins from across the entire SARS-CoV-2 genome.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
TVGN-489 is highly purified cytotoxic CD8+ T lymphocytes (CTLs) designed to detect and kill SARS-CoV-2 infected cells. TVGN-489 completed proof-of-concept clinical trial with zero treatment-related adverse events.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the SARS-CoV-2 genome.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
TVGN-489 is a highly purified, genetically unmodified SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, which is designed to detect targets spread across the entire viral genome.
Lead Product(s): TVGN-489
Therapeutic Area: Infections and Infectious Diseases Product Name: TVGN-489
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
